H B Fuller Company (FUL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of H B Fuller Company stock $39.46, price $49.86, that is 20.9% below the price, quality 53 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $47.03 – $83.17 · fair‑value band $19.20 – $51.30 · the $49.86 price screens above the $39.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow H B Fuller in your weekly email
Every Wednesday you see whether H B Fuller is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products.
Show moreShow less
It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions.
The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and medical and beauty.
The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets.
The Construction Adhesives segment provides products used for commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade.
The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.
Stock analysis
H B Fuller Company (FUL) currently trades at $49.86, while our model-based Fair Value estimate is $39.46, 21% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $60.91 per share, and 6 of the 23 models we run sit above the $49.86 price.
Bear case: the Dividend Discount group reads lowest at $12.43, and 17 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: $19.20 (bear) to $51.30 (bull), the price of $49.86 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
H B Fuller Company reported revenue of $3.5B in FY2025 versus $3.3B in FY2021, a compound +1.5%/yr. Reported net income was $152M in FY2025, compounding −1.5%/yr from FY2021.
Key figures
Market cap $2.7B Mid · P/E ratio 13.9 · P/S ratio 0.77 · EPS (TTM) $3.59 · Dividend yield 1.9% · Net margin 5.6% · Return on equity 9.6% · Return on assets (EBIT) 7.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −21%, FUL screens cheaper than that median.
Fair Value models
Bear$19.20Fair Value $39.46Bull$51.30
Price $49.86 · Downside -20.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then ($2.48 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 9 officers or directors bought shares worth $1.1M, most recently on Oct 16, 2026. Over the same period, one person sold shares worth $593,356. Buying cluster
BuyMuhammad Shahbaz MalikSenior VP, BAS479 shares at $52.23$25,000Oct 16, 2026
BuyR Jeffrey BaillyDirector10,000 shares at $50.00$500,000Oct 7, 2026
BuyCeline Christine MartinDirector465 shares at $49.50$22,998Sep 30, 2026
BuyMichael J HappeDirector2,000 shares at $49.63$99,250Sep 29, 2026
BuySrilata ZaheerDirector2,040 shares at $49.08$100,119Sep 29, 2026
BuyCharles T LauberDirector2,005 shares at $49.87$99,989Sep 29, 2026
BuyThomas W HandleyDirector2,000 shares at $49.41$98,820Sep 28, 2026
BuyDaniel L FlornessDirector2,030 shares at $49.34$100,160Sep 28, 2026
SaleNathan D. WeaverExec VP, Business Transform.2× since Nov 13, 2025: 16,636 shares, avg. $60.49$1.0MAug 11, 2026
Plus 1 more entries from the last 12 months.
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Start year 2020 (pandemic). Over 10 years: +5.2% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.0%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.8% vs 5.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 12%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +18.9% a year for the price and +3.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (89 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: The business shows moderate financial returns but lacks clear evidence of durable competitive advantage, with expansion into medical adhesives providing the main area of portfolio development.
Main risk: The added leverage required to fund the medical adhesives acquisition risks constraining financial flexibility and increasing refinancing pressure across the specialty chemicals operations.
H.B. Fuller is issuing new senior notes to help fund its planned acquisition of Advanced Medical Solutions and refinance other debt. The move expands exposure to medical adhesives while an activist continues pressing for a sale of the building adhesives unit. Our models see the stock as overvalued. Will the medical acquisition deliver enough portfolio improvement to justify the added leverage and ongoing divestiture pressure?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 726 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−20.9% · Above median
Profitability
Return on equity (12 months)9.6% · Above median
Return on assets2.9% · Below median
Net margin (12 months)5.6% · Above median
Operating margin (12 months)13.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)5.2% · Below median
Dividend yield (12 months)1.9% · Above median
Balance sheet
Debt / equity1.01× · Highest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (12 months)13.9× · Cheaper than median
P/B1.37× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)0.77× · Cheaper than median
Price / free cash flow (fiscal year)22.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "H B Fuller Company Fair Value". https://www.fairvalue-calculator.com/stock/FUL
Frequently asked questions
Is H B Fuller Company (FUL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $39.46 versus a price of $49.86, about 21% lower (overvalued).
What is the fair value of FUL?
Our model-based fair value for H B Fuller Company is $39.46 (as of Nov 8, 2026), built from audited fundamentals. The current price: $49.86.
What is the quality score of FUL?
H B Fuller Company has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for H B Fuller Company (FUL)?
Our model-based price target is the fair value of $39.46 (as of Nov 8, 2026) from 23 valuation models. Cautious scenario $19.20, optimistic scenario $51.30. It is a calculation from audited fundamentals, not an analyst target.
What is the H B Fuller Company stock forecast for 2026?
Our models put fair value at $39.46, about 21% lower versus a price of $49.86 (overvalued). Cautious scenario $19.20, optimistic scenario $51.30. The calculation is refreshed regularly with new filings.
What is the revenue of H B Fuller Company (FUL)?
H B Fuller Company reported trailing-twelve-month revenue of about $3.6B (latest available figure, as of Nov 8, 2026).
Does H B Fuller Company pay a dividend?
H B Fuller Company currently shows a dividend yield of 1.93% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of H B Fuller Company (FUL) and when is the ex-dividend date?
H B Fuller Company pays a dividend of $0.96 per share a year, a dividend yield of 1.9%. The last ex-dividend date was Oct 15, 2026. A dividend has been paid every year since at least 1985. The payout ratio is 21.4% of earnings (on adjusted earnings, reported 26.7%). Free cash flow covers the dividend 2.35 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into H B Fuller Company (FUL)?
For today's price to be fair in a discounted-cash-flow model, H B Fuller Company would have to grow free cash flow by +21.8 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.5 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of FUL use?
Our models discount H B Fuller Company at 9.7 %: a base by market capitalisation (mid), damped by beta 0.99, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For H B Fuller Company that is +21.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has H B Fuller Company (FUL) delivered so far?
Over the past 5 years revenue at H B Fuller Company grew +4.5 % a year. The price currently implies free-cash-flow growth of +21.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of H B Fuller Company (FUL) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into H B Fuller Company (+21.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of H B Fuller Company (FUL)?
The free-cash-flow yield on the price is 4.43 %: that much free cash flow H B Fuller Company produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of H B Fuller Company (FUL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For H B Fuller Company it is $39.46 per share (as of Nov 8, 2026), against a price of $49.86. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is H B Fuller Company stock overvalued or undervalued in 2026?
As of Nov 8, 2026, FUL trades above its calculated fair value: price $49.86, fair value $39.46, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FUL?
No. The price is what the market pays today ($49.86); the fair value is what the company's own numbers justify ($39.46). For H B Fuller Company the two are $10.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is H B Fuller Company worth?
The market values H B Fuller Company at about $2.7B (market capitalisation, as of Nov 8, 2026). Per share that is $49.86; our models calculate a fair value of $39.46 per share.
What do the bullish and bearish scenarios say about FUL?
Our models span a range for H B Fuller Company: cautious scenario $19.20, base $39.46, optimistic $51.30 per share (as of Nov 8, 2026, price $49.86). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FUL?
H B Fuller Company trades at a price-to-earnings ratio of 13.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $39.46 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 14.5 (reported for FY2025: 18.1). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 8 of the years ex one-offs: 22.8. Other multiples: PEG 2.2, P/B 1.4, P/S 0.8, EV/EBITDA 7.6.
What is the PEG ratio of FUL?
The PEG ratio of H B Fuller Company is 2.20 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of H B Fuller Company (FUL)?
Balance-sheet figures for H B Fuller Company (as of Nov 8, 2026): return on equity 9.6%, debt of 1.01 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is FUL from its 52-week high?
H B Fuller Company trades at $49.86, about 25% below its 52-week high of $66.59 and 3% above the low of $48.64 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $39.46 is for.
Which stocks are comparable to H B Fuller Company?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is H B Fuller Company stock attractive at the current price?
The data as of Nov 8, 2026: price $49.86, calculated fair value $39.46 (−21%), Quality Score 53/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FUL calculated?
We run H B Fuller Company through 23 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $39.46 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. H B Fuller Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of H B Fuller Company (FUL)?
The closing price on Nov 6, 2026 was $49.86. Our model-based fair value is $39.46, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with H B Fuller Company right now?
The model range is unusually wide ($19.20 to $51.30). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of H B Fuller Company (FUL) come from?
Earnings per share at H B Fuller Company grew +4.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.9 %, EBIT margin +2.7 %, tax rate +0.3 %, residual (interest, one-offs) −3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of H B Fuller Company
How large is the market capitalisation of H B Fuller Company (FUL)?
The market capitalisation of H B Fuller Company is $2.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of H B Fuller Company (FUL)?
The price-to-sales ratio of H B Fuller Company is 0.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of H B Fuller Company (FUL)?
Earnings per share at H B Fuller Company are $3.59 (price ÷ EPS = P/E 13.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of H B Fuller Company (FUL)?
The dividend yield of H B Fuller Company is 1.9% (payout 21.4%, on adjusted earnings, reported 26.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of H B Fuller Company (FUL)?
The net margin of H B Fuller Company is 5.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of H B Fuller Company (FUL)?
The return on equity (ROE) of H B Fuller Company is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of H B Fuller Company (FUL)?
On an EBIT basis the return on assets of H B Fuller Company is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of H B Fuller Company (FUL)?
The operating margin of H B Fuller Company is 13.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at H B Fuller Company (FUL)?
Revenue at H B Fuller Company is growing +5.2% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at H B Fuller Company (FUL)?
Earnings per share at H B Fuller Company are growing +18.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does H B Fuller Company (FUL) carry?
The net debt of H B Fuller Company is $1.9B (fiscal year 2025, ≈ 15.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch H B Fuller Company in the live analysis
One click puts H B Fuller Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026